Pfizer Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Exclusive Supply and Marketing Agreement for Pfizer Limited s brands Corex Dx,Corex LS, Dolonex, and Neksium with Cipla Limited.".
Press Release Dec 19 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Pfizer Limited has announced an exclusive supply and marketing agreement with Cipla Limited for several of its brands in India. The agreement covers the marketing and distribution of Corex Dx, Corex LS, Dolonex, and Neksium for an initial period of five years. This partnership aims to enhance the availability of these key brands across the country, leveraging Cipla's extensive distribution network. Pfizer will continue to manufacture and supply these medicines to Cipla under the terms of the agreement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Pfizer
- Pfizer: & Cipla Announce Exclusive Marketing and Distribution Partnership for Select Brands in India
- Annual Return – 2024-25
- Pfizer: Unaudited Results – Quarter Ended June 30, 2025
- Press Release Aug 11 2025
- Draft Annual Return 2024-25
Later from Pfizer
- Pfizer: Unaudited Results – Quarter ended December 31, 2025
- Pfizer: Audited Results - Year ended March 31, 2026
Follow Pfizer into a list and get an email when it puts out news.
Follow Pfizer